Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Impact of p-mTOR expression on molecular-guided therapy in PDAC

Hossein Taghizadeh • 23 Jun 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Pancreatic Cancer Everolimus

Hossein Taghizadeh, MD, Medical University of Vienna, Vienna, Austria, outlines the significance of phosphorylated mTOR (p-mTOR) expression on molecular guided therapy strategies in refractory metastatic pancreatic ductal adenocarcinoma (PDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Hossein Taghizadeh

4:18
Issues with molecular guided therapy in solid tumours
Hossein Taghizadeh • 23 Jun 2020
2:16
Efficacy of nanoliposomal irinotecan in biliary tract cancer
Hossein Taghizadeh • 22 Jun 2020
2:51
Impact of COVID-19 in Austria
Hossein Taghizadeh • 30 Jun 2020

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals